Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study
Authors' conclusion
iGlarLixi provides improved glycaemic control at lower insulin doses with reduced risk of hypoglycaemia in Chinese adults with suboptimally controlled T2D on OADs, regardless of baseline age, disease duration or HbA1c.
Study context
- Population
- Chinese adults with T2D suboptimally controlled on oral antidiabetic drugs; subgroups by baseline age (<65, ≥65 years), T2D duration (<10, ≥10 years) and HbA1c (≥7% to ≤8%, >8% to ≤9%, >9%)
- Participants
- 582 adults
- Comparison
- iGlarLixi vs IDegAsp
- iGlarLixin = 291
- IDegAspn = 291reference
Methodological detailssubgroup analyses
- Subgroup analyses
Primary result
As reported in the abstract
HbA1c reduction by subgroup (baseline age, T2D duration, HbA1c) · Week 24
- HbA1c reductions greater with iGlarLixi vs IDegAsp, with no treatment-by-subgroup interactions for baseline age, T2D duration or HbA1c
- Post hoc
Further findings
Other glycaemic outcomes, insulin dose and body weight by subgroup
- Change generally showed no interaction across subgroups
Total daily insulin dose by subgroup · during treatment
- Consistently lower with iGlarLixi vs IDegAsp in all subgroups
Safety
Hypoglycaemia event rates by subgroup
- Consistently lower with iGlarLixi vs IDegAsp in all subgroups
Original publication
Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study. Diabetes Obes Metab. Published 19 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →